Bortezomib is owned by Fresenius Kabi Usa.
Bortezomib contains Bortezomib.
Bortezomib has a total of 1 drug patent out of which 0 drug patents have expired.
Bortezomib was authorised for market use on 06 November, 2017.
Bortezomib is available in powder;intravenous dosage forms.
The generics of Bortezomib are possible to be released after 03 November, 2032.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8962572||FRESENIUS KABI USA||Bortezomib formulations|| |
(9 years from now)
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 06 November, 2017
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic